New Pharmacological Strategies to Increase cGMP
作者： Alessia Buglioni , John C. Burnett
DOI: 10.1146/ANNUREV-MED-052914-091923
关键词: Cyclic guanosine monophosphate 、 Phosphodiesterase 3 、 Neprilysin 、 Signal transduction 、 Endocrinology 、 Enzyme activator 、 Pathogenesis 、 Biology 、 Second messenger system 、 Receptor 、 Internal medicine
摘要: The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many human organ tissues. Its concentration increases response to the activation of receptor enzymes called guanylyl cyclases (GCs). Different ligands bind GCs, generating second messenger cGMP, which turn leads a variety biological actions. A deficit or dysfunction this pathway at cardiac, vascular, and renal levels manifests cardiovascular diseases such as heart failure, arterial hypertension, pulmonary hypertension. An impairment cGMP also may be involved pathogenesis obesity well dementia. Therefore, agents enhancing generation for treatment these conditions have been intensively studied. Some already approved, others are currently under investigation. This review discusses potential novel drugs directly indirectly targeting progress research date.
elsevier.com
sci-hub.se 参考文章(64)
Kris A. Steinbrecher, The multiple roles of guanylate cyclase C, a heat stable enterotoxin receptor. Current Opinion in Gastroenterology. ,vol. 30, pp. 1- 6 ,(2014) , 10.1097/MOG.0000000000000020
Camila Bononi Almeida, Christoph Scheiermann, Jung-Eun Jang, Colette Prophete, Fernando Ferreira Costa, Nicola Conran, Paul S. Frenette, Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice Blood. ,vol. 120, pp. 2879- 2888 ,(2012) , 10.1182/BLOOD-2012-02-409524
Fima Macheret, Denise Heublein, Lisa C. Costello-Boerrigter, Guido Boerrigter, Paul McKie, Diego Bellavia, Sarah Mangiafico, Yasuhiro Ikeda, Kent Bailey, Christopher G. Scott, Sharon Sandberg, Horng H. Chen, Lorenzo Malatino, Margaret M. Redfield, Richard Rodeheffer, John Burnett, Alessandro Cataliotti, Human Hypertension Is Characterized by a Lack of Activation of the Antihypertensive Cardiac Hormones ANP and BNP Journal of the American College of Cardiology. ,vol. 60, pp. 1558- 1565 ,(2012) , 10.1016/J.JACC.2012.05.049
Zemin Cao, Louise M. Burrell, Ilkka Tikkanen, Fabrice Bonnet, Mark E. Cooper, Richard E. Gilbert, Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney International. ,vol. 60, pp. 715- 721 ,(2001) , 10.1046/J.1523-1755.2001.060002715.X
Thomas J. Wang, Martin G. Larson, Daniel Levy, Emelia J. Benjamin, Eric P. Leip, Peter W.F. Wilson, Ramachandran S. Vasan, Impact of Obesity on Plasma Natriuretic Peptide Levels Circulation. ,vol. 109, pp. 594- 600 ,(2004) , 10.1161/01.CIR.0000112582.16683.EA
James R. Klinger, Steven H. Abman, Mark T. Gladwin, Nitric Oxide Deficiency and Endothelial Dysfunction in Pulmonary Arterial Hypertension American Journal of Respiratory and Critical Care Medicine. ,vol. 188, pp. 639- 646 ,(2013) , 10.1164/RCCM.201304-0686PP
Valentina Cannone, Guido Boerrigter, Alessandro Cataliotti, Lisa C. Costello-Boerrigter, Timothy M. Olson, Paul M. McKie, Denise M. Heublein, Brian D. Lahr, Kent R. Bailey, Maurizio Averna, Margaret M. Redfield, Richard J. Rodeheffer, John C. Burnett, A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. Journal of the American College of Cardiology. ,vol. 58, pp. 629- 636 ,(2011) , 10.1016/J.JACC.2011.05.011
C.M. O'Connor, R.C. Starling, A.F. Hernandez, P.W. Armstrong, K. Dickstein, V. Hasselblad, G.M. Heizer, M. Komajda, B.M. Massie, J.J.V. McMurray, M.S. Nieminen, C.J. Reist, J.L. Rouleau, K. Swedberg, K.F. Adams, S.D. Anker, D. Atar, A. Battler, R. Botero, N.R. Bohidar, J. Butler, N. Clausell, R. Corbalán, M.R. Costanzo, U. Dahlstrom, L.I. Deckelbaum, R. Diaz, M.E. Dunlap, J.A. Ezekowitz, D. Feldman, G.M. Felker, G.C. Fonarow, D. Gennevois, S.S. Gottlieb, J.A. Hill, J.E. Hollander, J.G. Howlett, M.P. Hudson, R.D. Kociol, H. Krum, A. Laucevicius, W.C. Levy, G.F. Méndez, M. Metra, S. Mittal, B.-H. Oh, N.L. Pereira, P. Ponikowski, W.H.W. Tang, S. Tanomsup, J.R. Teerlink, F. Triposkiadis, R.W. Troughton, A.A. Voors, D.J. Whellan, F. Zannad, R.M. Califf, Effect of nesiritide in patients with acute decompensated heart failure. The New England Journal of Medicine. ,vol. 365, pp. 32- 43 ,(2011) , 10.1056/NEJMOA1100171
Dougal R McClean, Hamid Ikram, Amanda H Garlick, A.Mark Richards, M.Gary Nicholls, Ian G Crozier, The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. Journal of the American College of Cardiology. ,vol. 36, pp. 479- 486 ,(2000) , 10.1016/S0735-1097(00)00741-5
Guido Boerrigter, John C. Burnett, Soluble guanylate cyclase: not a dull enzyme. Circulation. ,vol. 119, pp. 2752- 2754 ,(2009) , 10.1161/CIRCULATIONAHA.109.860288